Guidance

All influenza vaccines marketed in the UK for the 2025 to 2026 season (text version)

Updated 13 February 2025

© Crown copyright 2025

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at https://www.gov.uk/government/publications/influenza-vaccines-marketed-in-the-uk/all-influenza-vaccines-marketed-in-the-uk-for-the-2025-to-2026-season-text-version

Supplier Product Vaccine type Age indications Ovalbumin content micrograms/dose Contact details
AstraZeneca UK Ltd Fluenz® Trivalent LAIV (live attenuated influenza vaccine) supplied as nasal spray suspension From 24 months to less than 18 years of age Less than 0.024 micrograms per 0.2 ml dose 0845 139 0000
Sanofi Vaxigrip [footnote 1] TIVe (standard egg- grown trivalent influenza vaccine), split virion, inactivated From 6 months Equal to or less than 0.05 micrograms per 0.5 ml dose 0800 854 430
Viatris Influvac® sub-unit TIV▼ TIVe (standard egg-grown trivalent influenza vaccine) surface antigen, inactivated From 6 months Equal to or less than 0.1 micrograms per 0.5 ml dose 0800 358 7468
CSL Seqirus UK Cell-based Trivalent Influenza Vaccine Seqirus▼ TIVc (cell-based Trivalent influenza vaccine) surface antigen, inactivated From 6 months Egg-free 0345 0093 804
Sanofi Supemtek TIVr▼ [footnote 1] Supemtek TIV (trivalent influenza vaccine (recombinant, prepared in cell culture) ) From 18 years None 0800 854 430
Sanofi Efluelda TIV-HD▼ [footnote 1] TIV-HD (High-dose egg-grown trivalent influenza vaccine), split virion, inactivated 60 micrograms HA/strain From 60 years Equal to or less than 1 microgram per 0.5ml dose 0800 854 430
CSL Seqirus UK Adjuvanted Trivalent Influenza Vaccine Seqirus ▼ aTIV (adjuvanted egg- grown Trivalent influenza vaccine) surface antigen, inactivated, adjuvanted with MF59C.1 From 50 years Equal to or less than 1 microgram per 0.5ml dose 0345 0093 804

  1. Sanofi intends to supply trivalent formulations for the 2025 to 2026 season. Relevant license applications are under assessment and Medicines and Healthcare products Regulatory Agency (MHRA) approval is pending. Other potential formulations (quadrivalent) would have the same antigen content per strain, and ovalbumin content threshold (where relevant) as presented in the table. ↩ ↩2 ↩3

Back to top